206555-66-0

Basic information

• Product Name: 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE
• Synonyms: IFLAB-BB F0147-0127;1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE;1-(2-Amino-4-phenyl-1,3-thiazol-5-yl)ethanone;1-(2-amino-4-phenylthiazol-5-yl)ethan-1-one
• CAS NO: 206555-66-0
• Molecular Formula: C11H10N2OS
• Molecular Weight: 218.27
• Mol File: 206555-66-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE(206555-66-0)
• EPA Substance Registry System: 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE(206555-66-0)

Safety Data

• Hazardous Substances Data: 206555-66-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE is used as a key intermediate in the synthesis of various organic compounds. Its unique structural features, including the thiazole ring and the attached amino and phenyl groups, make it a valuable building block for creating a wide range of molecules with diverse properties and applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE is employed as a starting material for the development of new pharmaceuticals. Its structural characteristics allow for the design and synthesis of potential drug candidates with targeted biological activities, making it a promising compound for further research and development.
Used in Pharmaceutical Applications:
Due to its structural features, 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE may have potential pharmaceutical applications. 1-(2-AMINO-4-PHENYL-THIAZOL-5-YL)-ETHANONE's thiazole and phenyl groups can be modified to create new molecules with specific biological activities, which could be used as therapeutic agents for various medical conditions. Further research and development are necessary to explore and validate these potential applications.

Upstream product

• 1361413-53-7 N-(bis(4-methoxybenzyl)carbamothioyl)benzamide 
• 17356-08-0 thiourea 
• 93-91-4 1-phenylbutan-1,3-dione 

Relevant articles and documents

Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays

Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. It is caused by different mutations in the cystic fibrosis transmembrane regulator protein (CFTR) gene, with F508del being the most common. During the last y

TBHP/AIBN-Mediated Synthesis of 2-Amino-thioazoles from Active Methylene Ketones and Thiourea under Metal-free Conditions

A new oxidative system of tert-butyl hydroperoxide (TBHP)/azodiisobutyronitrile (AIBN) has been used for the first time for a convenient, metal-free synthesis of substituted 2-aminothioazoles from active methylene ketone derivatives and thiourea. The reaction is postulated to proceed via an oxidative cyclization initiated by a radical process and followed by a condensation reaction.

Method for synthesizing 2-aminothiazole derivative

The invention discloses a method for synthesizing a 2-aminothiazole derivative. The method comprises the following steps: by taking a ketone derivative (I) with an electron withdrawing group at the alpha position and thiourea (II) as raw materials, t-buty

Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors

Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

THERAPEUTIC AGENT FOR CANCER

A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1? a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2? unsubstituted thiazol-2-yl group, or 3? unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ―CONH―E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.

INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT

A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -X-E wherein each of X and E has the same meaning as that defined above.

INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES

A medicament having inhibitory activity against NF- κ B activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a connecting group, A represents hydrogen atom or acetyl group, E represents an aryl group or a heteroaryl group, and ring X represents an arene or a heteroarene.